TCT-8 Updated 30-Day Outcomes for the U.S. Early Feasibility Study of the SAPIEN M3 Transcatheter Mitral Valve Replacement System
2019
Our aim was to determine the initial technical feasibility, clinical safety, and efficacy of the SAPIEN M3 System in patients with severe mitral regurgitation (MR). Mitral valve surgery is currently recommended in patients with severe, symptomatic MR. The SAPIEN M3 System is a novel, transvenous,
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
8
Citations
NaN
KQI